계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
ImmunoMet Therapeutics
company
About
ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $5M
- Industries
- Biopharma,Biotechnology,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$12M
ImmunoMet Therapeutics has raised a total of
$12M
in funding over 2 rounds. Their latest funding was raised on
Feb 8, 2021 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 8, 2021 | Series Unknown | $7M | 1 | — | — | Detail |
| Mar 7, 2017 | Series B | $5M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
ImmunoMet Therapeutics is funded by 1 investors.
SL Investment
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
SL Investment
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
